Drug intelligence / Profile preview

HN-0001

Development stage: Unknown
Lead developer: Helix Nanotechnologies
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

HN-0001 is a next-generation mRNA vaccine candidate developed by Helix Nanotechnologies (HelixNano) for the prevention of COVID-19. The vaccine utilizes a proprietary mRNA platform designed to enhance the breadth and durability of the immune response against SARS-CoV-2 variants. HN-0001 is delivered via lipid nanoparticles (LNPs) and is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and immunogenicity in healthy adults. The development program focuses on addressing the limitations of first-generation mRNA vaccines by optimizing the digital sequence of the mRNA to improve antigen expression and immune recognition.

Other names: HelixNano COVID-19 vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on HN-0001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HN-0001.

Explore the full profile